Website: N/A
Stock Symbol: NASDAQ: NABI
Market Value: N/A (in millions)
We are a biopharmaceutical company focused on the development of products that
address unmet medical needs in the areas of nicotine addiction and infectious
disease. We leverage our experience and knowledge in powering the human immune
system to target serious medical conditions in these areas. Our lead products in
development are NicVAX® [Nicotine Conjugate Vaccine], an innovative and
proprietary investigational vaccine for treatment of nicotine addiction and
prevention of smoking relapse, and StaphVAX® [Staphylococcus aureus Vaccine], a
new pentavalent vaccine designed to prevent S.aureus infections including those
infections caused by the most dangerous antibiotic-resistant strains of
S.aureus.
NicVAX is an investigational vaccine based on patented technology.